SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Webhead who wrote (1613)10/30/1998 8:29:00 PM
From: DMB1 Recommendation  Read Replies (1) of 1762
 
Re: "I ran a quick literature search to try and find out how Rituxan actually kills the lymphoma cells. All I found was that some cells die by complement activation (where the immune system attacks and causes the rupture of the target cell) and others by other means. In other words, not very informative! Perhaps someone more familiar with Rituxan's mode of action could chime in here."

I saw a presentation about a year ago where several antibodies were compared in an in vitro cell lysis assay (a test tube experiment on cell killing). All 5 antibodies were monoclonals directed at a specific 5 aminoacid portion of the CD20 molecule. One of the antibodies was Rituxan (another was the Coulter anti-B1 antibody). Only the Rituxan produced cell lysis in this assay.

How to interpret this observation? Beats me, but I would think that it is not likely an "immune" effect or a "complement" mediated effect. Makes me wonder if Rituxan is acting by affecting a signalling pathway of some sort.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News